A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

Pfizer

Status: Completed

Conditions: Infections, Pneumococcal; HIV; Pneumonia

Treatments: Biological: Vaccine Administration

Study type: Observational

Funder types: Industry

Identifiers

NCT05794191

B1851217

NCT05794191 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV.

The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is spread into the bloodstream.

All participants in the study will be identified in health care databases. Adults with HIV will be identified by looking for a medical diagnosis that has confirmed HIV from the databases. Vaccination will be identified in the databases by looking for vaccine administration or for PCV13.

Participants will be followed in the databases to see if they have one of the diseases mentioned above or not. The number of vaccinated participants with the diseases will be compared to the number participants without the vaccines but with the diseases. This will help to understand how well the vaccine worked.

Enrollment: 350,399 patients

Sex: All

Ages: 18 to 89 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. HIV infection defined as at least one inpatient or ≥2 outpatient codes related to HIV at least 30 days but no more than 730 days apart
2. At least 18 years of age at the time of the first HIV-related code
3. At least six months of continuous enrollment in medical and pharmacy plans after the first HIV-related code

Exclusion criteria

1. Evidence of PCV13 vaccination before the first HIV-related code

Trial design

350,399 participants in 1 patient group

Persons living with HIV (PLWH)

Description:

Adults with HIV

Treatment:

Biological: Vaccine Administration